PHAT vs. ATXS, AVBP, ALT, STOK, KRRO, ANAB, CALT, CMPS, PAHC, and OLMA
Should you be buying Phathom Pharmaceuticals stock or one of its competitors? The main competitors of Phathom Pharmaceuticals include Astria Therapeutics (ATXS), ArriVent BioPharma (AVBP), Altimmune (ALT), Stoke Therapeutics (STOK), Korro Bio (KRRO), AnaptysBio (ANAB), Calliditas Therapeutics AB (publ) (CALT), COMPASS Pathways (CMPS), Phibro Animal Health (PAHC), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical preparations" industry.
Astria Therapeutics (NASDAQ:ATXS) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, community ranking, institutional ownership, risk and dividends.
Astria Therapeutics received 489 more outperform votes than Phathom Pharmaceuticals when rated by MarketBeat users. Likewise, 72.48% of users gave Astria Therapeutics an outperform vote while only 65.98% of users gave Phathom Pharmaceuticals an outperform vote.
Astria Therapeutics currently has a consensus price target of $21.25, indicating a potential upside of 136.11%. Phathom Pharmaceuticals has a consensus price target of $21.33, indicating a potential upside of 132.39%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Astria Therapeutics is more favorable than Phathom Pharmaceuticals.
Astria Therapeutics' return on equity of 0.00% beat Phathom Pharmaceuticals' return on equity.
Astria Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500.
In the previous week, Astria Therapeutics and Astria Therapeutics both had 6 articles in the media. Astria Therapeutics' average media sentiment score of 0.11 beat Phathom Pharmaceuticals' score of -0.20 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media.
99.0% of Astria Therapeutics shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 3.4% of Astria Therapeutics shares are held by insiders. Comparatively, 24.1% of Phathom Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Astria Therapeutics has higher earnings, but lower revenue than Phathom Pharmaceuticals. Astria Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Astria Therapeutics beats Phathom Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get Phathom Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PHAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phathom Pharmaceuticals Competitors List
Related Companies and Tools
